INSERM, U1070, 1 rue Georges Bonnet, 86022 Poitiers, France.
Int J Pharm. 2012 Oct 15;436(1-2):833-9. doi: 10.1016/j.ijpharm.2012.07.036. Epub 2012 Jul 28.
In this work a new formulation of inhalable rifampicin-loaded PLGA microspheres (RIF-MS) is proposed for the management of tuberculosis treatment. For their formulation, the non-biodegradable polyvinyl alcohol surfactant was replaced with a biodegradable and biocompatible sucrose ester, sucrose palmitate. The effects of critical process and formulation parameters have been investigated and the obtained microspheres were characterized in terms of size, morphology, encapsulation efficiencies and RIF release profile. The optimized RIF-MS showed high drug loading (34.2%, w/w), an aerodynamic diameter compliant with deep lung delivery and an in vitro gradual and almost complete drug release over a week. The drug release data fitted well to the Higuchi models suggesting a drug release governed by Fickian diffusion. The RIF-MS uptake qualitative and quantitative studies on ex vivo rat alveolar macrophages (AM) revealed an efficient internalization of RIF-MS and their location in the perinuclear area. RIF intracellular levels were 7-fold higher in AM incubated with RIF-MS than with an equivalent amount of free RIF.
本工作提出了一种新的可吸入利福平载药 PLGA 微球(RIF-MS)制剂,用于结核病治疗。在其制剂中,不可生物降解的聚乙烯醇表面活性剂被可生物降解和生物相容的蔗糖棕榈酸酯所取代。考察了关键工艺和制剂参数的影响,并对所得微球的粒径、形态、包封效率和 RIF 释放特性进行了表征。优化的 RIF-MS 具有较高的载药量(34.2%,w/w)、符合深肺递送的空气动力学直径和体外一周内逐渐且几乎完全的药物释放。药物释放数据与 Higuchi 模型拟合良好,表明药物释放受菲克扩散控制。RIF-MS 在离体大鼠肺泡巨噬细胞(AM)上的摄取定性和定量研究表明,RIF-MS 被有效内化,并位于核周区。与等量游离 RIF 孵育的 AM 相比,RIF-MS 中的 RIF 细胞内水平高 7 倍。